Medical Bulletin 28/December/2021

A team of researchers in a new study published in JAMA Neurology have developed and validated a tool that can be helpful for doctors in determining epilepsy patients who will not benefit from invasive stereoelectroencephalography (SEEG). This in turn will reduce the unnecessary invasive diagnostic burden on patients and also the overutilization of limited health care resources.

The researchers wrote, "high specificity in score development and validation confirms that the 5-SENSE score may predict patients where SEEG is unlikely to identify a focal seizure-onset zone."

For more details, check out the full story on the link below:

Unilateral Palatally displaced canines (PDC) do not delay delay tooth formation and affect dental developmental age, according to a new study.

The study has been published in the American Journal of Orthodontics and Dentofacial Orthopedics.

Ranitidine, a competitive antagonist of histamine-2 receptors, is used widely for the treatment of peptic ulcer disease and mild to moderate reflux esophagitis. Due to the changing lifestyle with increasing sedentary habits and poor dietary choices, there is an increasing prevalence of increased gastric acid secretion and hence the increased use of antacids including ranitidine.

Amid the safety concerns for the use of ranitidine, a recent study has found the antacid to be safe to use including in children, pregnant women, and the elderly. In the review published in the Journal of Indian Medical Association, the researchers described ranitidine to be well tolerated with rare adverse and serious adverse events related to its use.

Urotronic, Inc., a Minnesota based medical device company, has announced that the U.S. Food and Drug Administration (FDA) has approved the Optilume Urethral Drug Coated Balloon for use in male urethral strictures. Optilume was granted CE mark approval for use in urethral strictures in 2020.